路透1月15日 - WuXi Biologics (Cayman) Inc 2269.HK:
中国药明生物、药明合联2268.HK、东曜药业1875.HK发布联合公告。
药明合联将以每股4.00港元的价格向东曜药业提出有条件现金收购要约，收购后者所有约7.73亿股股份。
报价较股份截至未受干扰日（包括当日）止30个交易日的平均收盘价1.86港元溢价约114.67%。交易资金将来自内部资源。
药明合联计划维持东曜药业在香港的上市地位。东曜药业股票将于1月15日恢复交易。
药明生物直接持有药明合联已发行股本总额的约50.63%。
浏览详情，请点击此处
(发稿 崔珠珠)
((Zhuzhu.Cui@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.